Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 22 of 33 · 1560 articles
If validated, a simple ultrasound-based score could reduce the need for invasive endoscopy to monitor disease activity in children with ulcerative colitis. Noninvasive monitoring is especially valuable in pediatrics.
Surgery remains an important treatment option for Crohn’s disease and may be considered earlier for some patients. Decisions about timing, technique, and perioperative care can affect long-term outcomes and recurrence...
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...
This study addresses whether removing the appendix changes long-term UC outcomes. People with UC or their clinicians might expect surgery to alter disease course; these real-world data suggest it generally does not for...
Many people with Crohn’s disease have ongoing inflammation despite stable medication. If dietary personalization can reduce inflammation, it could offer a nonpharmacologic add-on to help bridge gaps without immediate...
Most people with IBD can have children safely with modern treatments and planning; uncontrolled disease poses greater risks to pregnancy than continuing most IBD medications. Planning and specialist input before...
Researchers and clinicians looking for blood- or tissue-based molecular tests for IBD may find these integrated transcriptomic analyses useful because they identify candidate diagnostic biomarkers and highlight shared...
Oral signs such as persistent lip swelling can be an early presentation of Crohn’s disease in adolescents and may prompt testing that leads to earlier diagnosis and treatment.
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
Early, noninvasive biomarkers could help detect ulcerative colitis and related colorectal cancer risk sooner. This study identifies four serum-accessible proteins with promising diagnostic accuracy in the reported...
This trial directly informs a common clinical question: whether patients in deep remission can safely stop anti‑TNF therapy. Results show higher relapse risk after withdrawal, but many patients can be successfully...
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
The study proposes a targeted oral delivery method that could help concentrate anti-inflammatory natural compounds at inflamed colon sites, potentially improving treatment effectiveness for ulcerative colitis while...
CVID can cause GI problems that closely mimic Crohn’s disease, ulcerative colitis, or celiac disease and may change diagnostic and treatment choices. Gastroenterologists need to consider CVID when IBD presentations are...
A new investigational drug (BI 3032950) is being tested specifically for people with ulcerative colitis who did not do well on prior biologic or targeted treatments. If effective and safe, it could become another option...
People with Crohn’s disease who are overweight or have obesity may have different disease and treatment needs. This Phase 3 trial is testing whether adding tirzepatide to mirikizumab improves both disease outcomes and...
Mental health problems often begin before IBD is diagnosed and stay higher for years after; addressing psychiatric symptoms early could improve overall disease management and quality of life for people with Crohn’s...
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Endoscopy comfort and sedation differ between pediatric and adult settings, and worse adult experiences could deter young adults from needed surveillance or care. Addressing sedation choice, communication, and provider...
The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Genetics and genomics. The original article is from Cureus.
This paper suggests that epithelial barrier structure and function may be altered in very early onset pediatric IBD. That could help researchers study disease mechanisms and eventually guide targeted therapies for...
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.
Dual-energy CT quantification of creeping fat could offer a measurable imaging biomarker that reflects transmural inflammation and fibrosis in Crohn’s disease, potentially improving monitoring beyond mucosal healing.
The work narrows down which genes are likely influenced by Crohn’s disease–associated regulatory DNA in a specific gut immune cell type, helping researchers prioritize targets and understand disease mechanisms.
This study helps distinguish patterns of colorectal dysplasia seen in people without IBD from those seen in IBD, which may affect how pathologists and clinicians interpret biopsy findings and consider cancer risk and...
This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...
If epithelial cells themselves retain disease-linked programs, that could help explain persistent intestinal abnormalities in Crohn’s disease even during remission and point to new biomarker or therapeutic targets...
Fatigue is a frequent, impactful symptom in Crohn’s disease that often goes unmeasured in clinic visits. Knowing which assessment tools exist can help patients and clinicians recognize and address fatigue.
The work helps bridge genetic association signals and the specific immune cells in the intestine where they may act, offering new candidate genes and a method that can probe rare cell types important to IBD biology.
ILC3s live in the intestine and help regulate barrier function and inflammation, so mapping how genetic variants affect gene regulation in these rare cells helps connect inherited risk signals to plausible biology for...
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
Diet-based therapies like CDED + PEN may help control Crohn’s symptoms and improve nutrition without adding medications. This study suggests some adults can maintain remission and gain nutritional benefits over a year...
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
This review summarizes evidence on robotic surgery for IBD, which could affect surgical choices and expectations about recovery and risks for patients needing colorectal or pelvic operations. It suggests robotic...
Older adults with UC face different risks and treatment trade-offs than younger patients — higher infection and cancer risks, medication toxicities, and challenges with diagnosis and colonoscopy. Understanding these...
MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...
Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
This study could validate a noninvasive stool-test strategy (FIT + fecal calprotectin) to triage which long-standing UC patients need colonoscopy, potentially improving surveillance efficiency and adherence.
